Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N, Yamamoto A, Takesako K, Yamaguchi K, Akiyama Y

Oncol Rep. 2012 Oct;28(4):1131-8. doi: 10.3892/or.2012.1956. Epub 2012 Aug 7.

Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey

Bouchez C, Gervais F, Fleurance R, Palate B, Legrand JJ, Descotes J

J Toxicol Pathol. 2012 Jun;25(2):183-8.

Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial.

Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA

J Clin Oncol. 2012 May 14

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study.

Boulton C, Meiser K, David OJ, Schmouder R

J Clin Pharmacol. 2011 Dec 15. [Epub ahead of print]

Response to Cutaneous Immunization with Low-Molecular-Weight Subunit Keyhole Limpet Hemocyanin

Milgrom H, Kesler K, Byron M, Harbeck R, Holliday R, Leung DY.

Int Arch Allergy Immunol. 2011 Oct 28;157(3):269-27

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients.

Lesterhuis WJ, de Vries IJ, Aarntzen EA, de Boer A, Scharenborg NM, van de Rakt M, van Spronsen DJ, Preijers FW, Figdor CG, Adema GJ, Punt CJ

Br J Cancer. 2010 Oct 26;103(9):1415-21. Epub 2010 Oct 5

Higher whole-blood selenium is associated with improved immune responses in footrot-affected sheep

Jean A Hall, Rachel L Sendek, Rachel M Chinn, D Paul Bailey, Katie N Thonstad, Yongqiang Wang, Neil E Forsberg, William R Vorachek, Bernadette V Stang, Robert J Van Saun, and Gerd Bobe.

Vet Res. 2011; 42(1): 99

Developmental immunotoxicity of di-n-octyltin dichloride (DOTC) in an extended one-generation reproductive toxicity study

Tonk EC, de Groot DM, Penninks AH, Waalkens-Berendsen ID, Wolterbeek AP, Piersma AH, van Loveren H.

Toxicol Lett. 2011 Jul 28;204(2-3):156-63. Epub 2011 Apr 30.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. Epub 2011 Jul 19

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. Epub 2010 Nov 11